Literature DB >> 17080236

Stromal osteonectin overexpression is associated with poor outcome in patients with ampullary cancer.

Mark Bloomston1, E Christopher Ellison, Peter Muscarella, Osama Al-Saif, Edward W Martin, W Scott Melvin, Wendy L Frankel.   

Abstract

BACKGROUND: Osteonectin has been suggested to be important in the progression of pancreatic cancer but has not been correlated with survival. We determined the osteonectin expression and its influence on survival in patients with ampullary carcinoma.
METHODS: Tissue microarrays were constructed from the tumors of 56 patients with ampullary cancer undergoing pancreaticoduodenectomy. Immunohistochemical staining for osteonectin was undertaken and compared with staining in chronic pancreatitis (n = 13) and normal pancreas (n = 19). Survival curves were created by the Kaplan-Meier method and compared by log rank analysis. Median follow-up for all living patients with ampullary cancer was 69.6 months.
RESULTS: Osteonectin was significantly (P < .05, Fisher's exact test) overexpressed in the stroma of ampullary cancers (90%) relative to chronic pancreatitis (62%) and normal pancreas (0%). Tumors expressing osteonectin were more likely to have nodal metastases than those lacking osteonectin expression (48% vs. 0%, P = .06, Fisher's exact test) and showed decreased survival. Node-negative status, pylorus preservation at the time of pancreaticoduodenectomy, and lack of osteonectin expression were predictors of prolonged survival by multivariate analysis.
CONCLUSIONS: Although the importance of tumor-stroma interactions in periampullary cancers is not fully understood, our data suggest that osteonectin is an integral stromal element in ampullary cancers, and its overexpression is associated with decreased survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17080236     DOI: 10.1245/s10434-006-9128-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  Development of Secreted Protein and Acidic and Rich in Cysteine (SPARC) Targeted Nanoparticles for the Prognostic Molecular Imaging of Metastatic Prostate Cancer.

Authors:  Stephanie Thomas; Peter Waterman; Suelin Chen; Brett Marinelli; Marc Seaman; Scott Rodig; Robert W Ross; Lee Josephson; Ralph Weissleder; Kimberly A Kelly
Journal:  J Nanomed Nanotechnol       Date:  2011-08

Review 2.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 3.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

Review 4.  Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications.

Authors:  Xiangyu Kong; Lei Li; Zhaoshen Li; Keping Xie
Journal:  Cytokine Growth Factor Rev       Date:  2012-07-01       Impact factor: 7.638

Review 5.  TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.

Authors:  M Benavides; A Abad; I Ales; A Carrato; E Díaz Rubio; J Gallego; J García-Foncillas; C Grávalos; B Laquente; C Pericay; F Rivera; J Tabernero; E Aranda
Journal:  Clin Transl Oncol       Date:  2014-04-12       Impact factor: 3.405

6.  Coordinate loss of fragile gene expression in pancreatobiliary cancers: correlations among markers and clinical features.

Authors:  Mark Bloomston; Jeffrey Kneile; Matthew Butterfield; Mary Dillhoff; Peter Muscarella; E Christopher Ellison; W Scott Melvin; Carlo M Croce; Flavia Pichiorri; Kay Huebner; Wendy L Frankel
Journal:  Ann Surg Oncol       Date:  2009-05-12       Impact factor: 5.344

7.  Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin.

Authors:  Xiang-Qian Zhao; Jia-Hong Dong; Wen-Zhi Zhang; Zhe Liu
Journal:  Diagn Pathol       Date:  2011-10-13       Impact factor: 2.644

8.  SPARC: a matricellular regulator of tumorigenesis.

Authors:  Shanna A Arnold; Rolf A Brekken
Journal:  J Cell Commun Signal       Date:  2009-10-07       Impact factor: 5.782

Review 9.  Prognostic Value of SPARC in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Authors:  Wei Han; Fang Cao; Min-bin Chen; Rong-zhu Lu; Hua-bing Wang; Min Yu; Chun-tao Shi; Hou-zhong Ding
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

10.  Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma.

Authors:  Christopher Hartley; Daniel Rowan; Xiuxu Chen; Luisa Gomez-Arellano; Anna Marie West; Kiyoko Oshima; Alexander Craig Mackinnon
Journal:  Pract Lab Med       Date:  2020-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.